Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Eribulin Mesylate

FDA-approved product (solution, intravenous), marketed as Eribulin Mesylate, Halaven.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Eribulin Mesylate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Breast cancer
  • Breast carcinoma
  • Breast neoplasm
  • Cancer
  • Liposarcoma
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antineoplastic agents
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA46.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli41.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae39.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis53.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Eribulin Mesylate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Eribulin Mesylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

    NCT04579224 · start 2021-06-28

    Registered record
    Registry ID
    NCT04579224
    Conditions
    Metastatic Bladder Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Refractory Bladder Urothelial Carcinoma; Refractory Urothelial Carcinoma; Stage IV Bladder Cancer AJCC v8
    Interventions
    Biospecimen Collection; Bone Scan; Computed Tomography; Docetaxel; Eribulin Mesylate; Gemcitabine Hydrochloride; Magnetic Resonance Imaging; Paclitaxel; Sacituzumab Govitecan
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2021-06-28
    Completion
    2030-08-15
    Enrolment
    184

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Bladder Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Refractory Bladder Urothelial Carcinoma; Refractory Urothelial Carcinoma +1 more
    InterventionBiospecimen Collection; Bone Scan; Computed Tomography; Docetaxel +5 more
    PhasePhase 3
    Registry statusActive not recruiting

  • Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast Cancer

    NCT04624711 · start 2021-03-01

    Registered record
    Registry ID
    NCT04624711
    Conditions
    HER2-negative Breast Cancer
    Interventions
    Eribulin Mesylate; Anlotinib hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2021-03-01
    Completion
    2022-12
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHER2-negative Breast Cancer
    InterventionEribulin Mesylate; Anlotinib hydrochloride
    PhasePhase 2
    Registry statusUnknown

  • Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer

    NCT04745975 · start 2021-02-01

    Registered record
    Registry ID
    NCT04745975
    Conditions
    Triple Negative Breast Cancer
    Interventions
    Personalized treatment guided by mini-PDX and RNA sequencing; Nab paclitaxel; Eribulin; Vinorelbine; Gemcitabine; Capecitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2021-02-01
    Completion
    2023-01
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTriple Negative Breast Cancer
    InterventionPersonalized treatment guided by mini-PDX and RNA sequencing; Nab paclitaxel; Eribulin; Vinorelbine +2 more
    PhasePhase 2
    Registry statusUnknown

  • Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer

    NCT05206656 · start 2020-10-09

    Registered record
    Registry ID
    NCT05206656
    Conditions
    Metastatic Breast Cancer
    Interventions
    Eribulin Mesylate; Anlotinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-10-09
    Completion
    2022-07-20
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Breast Cancer
    InterventionEribulin Mesylate; Anlotinib
    PhasePhase 2
    Registry statusCompleted

  • A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC

    NCT04303741 · start 2020-03-25

    Registered record
    Registry ID
    NCT04303741
    Conditions
    Breast Cancer
    Interventions
    Camrelizumab; Apatinib; Eribulin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2020-03-25
    Completion
    2023-08-31
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionCamrelizumab; Apatinib; Eribulin
    PhasePhase 2
    Registry statusUnknown

  • Eribulin in mTNBC Patients

    NCT04541420 · start 2019-12-15

    Registered record
    Registry ID
    NCT04541420
    Conditions
    Breast Cancer
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2019-12-15
    Completion
    2020-12-20
    Enrolment
    208

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Trial With Eribulin or Eribulin+ Endocrine Therapy in Locally-recurrent or Metastatic Breast Cancer Patients

    NCT03795012 · start 2019-04-30

    Registered record
    Registry ID
    NCT03795012
    Conditions
    Breast Cancer
    Interventions
    Eribulin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2019-04-30
    Completion
    2021-03-31
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionEribulin
    PhasePhase 2
    Registry statusTerminated

  • Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer

    NCT03237780 · start 2018-07-20

    Registered record
    Registry ID
    NCT03237780
    Conditions
    Locally Advanced Bladder Urothelial Carcinoma; Locally Advanced Renal Pelvis Urothelial Carcinoma; Locally Advanced Ureter Urothelial Carcinoma; Locally Advanced Urethral Urothelial Carcinoma; Metastatic Bladder Urothelial Carcinoma; Metastatic Renal Pelvis Urothelial Carcinoma; Metastatic Ureter Urothelial Carcinoma; Metastatic Urethral Urothelial Carcinoma; Recurrent Bladder Urothelial Carcinoma; Recurrent Renal Pelvis Urothelial Carcinoma; Recurrent Ureter Urothelial Carcinoma; Recurrent Urethral Urothelial Carcinoma; Stage III Bladder Cancer AJCC v8; Stage III Renal Pelvis Cancer AJCC v8; Stage III Ureter Cancer AJCC v8; Stage III Urethral Cancer AJCC v8; Stage IV Bladder Cancer AJCC v8; Stage IV Renal Pelvis Cancer AJCC v8; Stage IV Ureter Cancer AJCC v8; Stage IV Urethral Cancer AJCC v8; Unresectable Bladder Urothelial Carcinoma; Unresectable Renal Pelvis Urothelial Carcinoma; Unresectable Ureter Urothelial Carcinoma; Unresectable Urethral Urothelial Carcinoma
    Interventions
    Atezolizumab; Biopsy Procedure; Biospecimen Collection; Computed Tomography with Contrast; Eribulin Mesylate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2018-07-20
    Completion
    2027-06-30
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLocally Advanced Bladder Urothelial Carcinoma; Locally Advanced Renal Pelvis Urothelial Carcinoma; Locally Advanced Ureter Urothelial Carcinoma; Locally Advanced Urethral Urothelial Carcinoma +20 more
    InterventionAtezolizumab; Biopsy Procedure; Biospecimen Collection; Computed Tomography with Contrast +1 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma

    NCT03526679 · start 2018-07-12

    Registered record
    Registry ID
    NCT03526679
    Conditions
    Leiomyosarcoma; Liposarcoma; Soft Tissue Sarcoma Adult; Advanced Cancer
    Interventions
    Eribulin; Lenvatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2018-07-12
    Completion
    2025-10-30
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeiomyosarcoma; Liposarcoma; Soft Tissue Sarcoma Adult; Advanced Cancer
    InterventionEribulin; Lenvatinib
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)

    NCT03441360 · start 2018-04-17

    Registered record
    Registry ID
    NCT03441360
    Conditions
    Relapsed/Refractory Rhabdomyosarcoma; Non-rhabdomyosarcoma Soft Tissue Sarcoma; Ewing Sarcoma
    Interventions
    Eribulin mesylate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-04-17
    Completion
    2022-01-21
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRelapsed/Refractory Rhabdomyosarcoma; Non-rhabdomyosarcoma Soft Tissue Sarcoma; Ewing Sarcoma
    InterventionEribulin mesylate
    PhasePhase 2
    Registry statusCompleted

  • Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy

    NCT03393741 · start 2018-01-29

    Registered record
    Registry ID
    NCT03393741
    Conditions
    Breast Cancer; Breast Neoplasms
    Interventions
    Taxane; Vinorelbine; Ixabepilone; Eribulin; Chemotherapy
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2018-01-29
    Completion
    2024-02-11
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Breast Neoplasms
    InterventionTaxane; Vinorelbine; Ixabepilone; Eribulin +1 more
    PhaseNot recorded
    Registry statusTerminated

  • SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer

    NCT03262935 · start 2017-12-15

    Registered record
    Registry ID
    NCT03262935
    Conditions
    Metastatic Breast Cancer
    Interventions
    (vic-)trastuzumab duocarmazine; Physician's choice
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-12-15
    Completion
    2022-06-30
    Enrolment
    437

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Breast Cancer
    Intervention(vic-)trastuzumab duocarmazine; Physician's choice
    PhasePhase 3
    Registry statusCompleted

  • A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer

    NCT03051659 · start 2017-03-22

    Registered record
    Registry ID
    NCT03051659
    Conditions
    Breast Cancer
    Interventions
    Eribulin Mesylate; Pembrolizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-03-22
    Completion
    2023-09-05
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionEribulin Mesylate; Pembrolizumab
    PhasePhase 2
    Registry statusCompleted

  • A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer

    NCT02623972 · start 2016-02-26

    Registered record
    Registry ID
    NCT02623972
    Conditions
    Inflammatory Breast Cancer; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
    Interventions
    Eribulin; Adriamycin; Cyclophosphamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2016-02-26
    Completion
    2026-12
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInflammatory Breast Cancer; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
    InterventionEribulin; Adriamycin; Cyclophosphamide
    PhasePhase 2
    Registry statusActive not recruiting

  • Evaluate the Safety Profile and Ability of TW1025 Oral Solution to Decrease Fatigue

    NCT02645175 · start 2016-01

    Registered record
    Registry ID
    NCT02645175
    Conditions
    Metastatic Breast Cancer; Fatigue
    Interventions
    TW1025; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2016-01
    Completion
    2018-12
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Breast Cancer; Fatigue
    InterventionTW1025; Placebo
    PhasePhase 2
    Registry statusTerminated